Merck's at-home antiviral COVID-19 pill gets U.S. authorisation
The Hindu
Molnupiravir was shown to reduce hospitalisations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness
The U.S. on Thursday authorised Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving the go-ahead to a similar but more effective treatment from Pfizer Inc.
Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalisations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
The U.S. Food and Drug Administration authorised Merck's drug to treat mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative COVID-19 treatments are not accessible or clinically appropriate.